Search research articles
Contact Us
Filters
Showing results (81-90 of 94) with videos related to
Page
of 10
Sort By:
Hematological Oncology
|
May 31, 2022
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials
Enrica Antonia Martino, Concetta Conticello, Elena Zamagni, et al.
Haematologica
|
March 19, 2026
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone
Carmine Liberatore, Alfonso Piciocchi, Donatella Vincelli, et al.
Haematologica
|
March 26, 2026
Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experience
Carmine Liberatore, Virginia Valeria Ferretti, Paola Tacchetti, et al.
European Journal of Haematology
|
January 15, 2026
Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations
Alessandro Corso, Monia Marchetti, Monica Galli, et al.
Annals of Hematology
|
October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy
Concetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.
European Journal of Haematology
|
October 30, 2021
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
Fortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Haematologica
|
April 30, 2025
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients
Gregorio Barilà, Angela Grassi, Concetta Conticello, et al.
Hematological Oncology
|
February 3, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study
Enrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Frontiers in Oncology
|
August 4, 2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
Fortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Haematologica
|
July 13, 2023
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials
Massimo Gentile, Ernesto Vigna, Salvatore Palmieri, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 94) with videos related to
Sort By:
Page
of 10
Hematological Oncology
|
May 31, 2022
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials
Enrica Antonia Martino, Concetta Conticello, Elena Zamagni, et al.
Haematologica
|
March 19, 2026
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone
Carmine Liberatore, Alfonso Piciocchi, Donatella Vincelli, et al.
Haematologica
|
March 26, 2026
Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experience
Carmine Liberatore, Virginia Valeria Ferretti, Paola Tacchetti, et al.
European Journal of Haematology
|
January 15, 2026
Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations
Alessandro Corso, Monia Marchetti, Monica Galli, et al.
Annals of Hematology
|
October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy
Concetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.
European Journal of Haematology
|
October 30, 2021
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
Fortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Haematologica
|
April 30, 2025
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients
Gregorio Barilà, Angela Grassi, Concetta Conticello, et al.
Hematological Oncology
|
February 3, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study
Enrica Antonia Martino, Daniele Derudas, Elena Rossi, et al.
Frontiers in Oncology
|
August 4, 2022
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
Fortunato Morabito, Elena Zamagni, Concetta Conticello, et al.
Haematologica
|
July 13, 2023
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials
Massimo Gentile, Ernesto Vigna, Salvatore Palmieri, et al.
Page
of 10